Avastin use extended

The licence for Avastin (bevacizumab) has been extended to include use in combination with paclitaxel for first-line treatment of patients with metastatic breast cancer.

Previously, bevacizumab was licensed for use in combination with intravenous 5-fluorouracil, folinic acid and irinotecan for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

Avastin must be administered under the supervision of a physician experienced in the use of antineoplastic products.

Further information: Roche 01707 366000

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases